Bharat Immunologicals & Biologicals Balance Sheet Health
Financial Health criteria checks 1/6
Bharat Immunologicals & Biologicals has a total shareholder equity of ₹787.1M and total debt of ₹743.6M, which brings its debt-to-equity ratio to 94.5%. Its total assets and total liabilities are ₹1.9B and ₹1.1B respectively.
Key information
94.5%
Debt to equity ratio
₹743.64m
Debt
Interest coverage ratio | n/a |
Cash | ₹89.09m |
Equity | ₹787.09m |
Total liabilities | ₹1.09b |
Total assets | ₹1.88b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 524663's short term assets (₹327.1M) do not cover its short term liabilities (₹990.5M).
Long Term Liabilities: 524663's short term assets (₹327.1M) exceed its long term liabilities (₹103.7M).
Debt to Equity History and Analysis
Debt Level: 524663's net debt to equity ratio (83.2%) is considered high.
Reducing Debt: 524663's debt to equity ratio has increased from 0% to 94.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if 524663 has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 524663 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.